Gene-editing field sees another merger, this time between Chroma Medicine and Nvelop Therapeutics

Two prominent gene-editing startups, Chroma Medicine and Nvelop Therapeutics, said Wednesday they will merge, forming a new company called nChroma Bio.

The merger will combine molecular machines Chroma was developing to modify genes without cutting DNA and technology Nvelop was developing to deliver DNA-modifying machinery to precise tissues in the body. 

advertisement

Leadership for the combined company argued it was a natural fit. In industry parlance, it joins a “delivery” company with a “cargo” company — fusing the two key pieces needed to build a genetic medicine.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe